NCT03958474View on ClinicalTrials.gov

Neurobehavioral Mechanisms of Choice in Opioid Use Disorder

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 16, 2019

Primary Completion Date

July 10, 2025

Study Completion Date

July 10, 2025

Conditions
Opioid Use Disorder
Interventions
DRUG

Oxycodone

Participants receive oxycodone or placebo.

DRUG

Remifentanil

Participants with a history of IV opioid use can opt to complete a session in which they receive remifentanil.

Trial Locations (1)

40536-0086

Laboratory of Human Behavioral Pharmacology, Lexington

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Joshua A. Lile, Ph.D.

OTHER

NCT03958474 - Neurobehavioral Mechanisms of Choice in Opioid Use Disorder | Biotech Hunter | Biotech Hunter